Contribute to the Future of Cancer Treatments!

DIA invites industry leaders to participate in our groundbreaking research study that contributes to the understanding of tolerability for immune-oncology (I-O) therapies in selected cancers.

Advancing Patient-Centric Care

At DIA, we recognize the importance of understanding tolerability as a crucial aspect of developing and delivering effective I-O therapies. As mandated by the 21st Century Cures Act, patient preferences play a vital role in shaping treatment programs and clinical decision-making.
Pioneering Tolerability Research

We are conducting a comprehensive research study to explore the definition of tolerability in I-O therapies for selected cancers. By participating in this study, industry leaders have an opportunity to contribute to the understanding and a consensus around the development of a tolerability PRO instrument(s) that will help collect valuable information directly from patients.

Overcoming Challenges Together

Collecting accurate and meaningful data on tolerability from patients is not without its challenges. That's why we need your expertise and support. Together, we can address these challenges and pave the way for improved patient-centered care in I-O therapy development.

If you are interested in joining the study working group, learning more, or have any other questions about the research study, please contact [email protected].